Author: Emma Mueller

by
CF Community, CF News, Research, Therapies
March 20, 2019

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Development...

by
CF Community, CF News, Research
March 20, 2019

Alcresta Therapeutics Receives 510(k) Clearance For Use of RELiZORB® in ChildrenRELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children Suffering from Fat MalabsorptionJuly 20, 2017 08:30 AM Eastern Daylight TimeWARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc., dedicated to developing...

by
Boomer Esiason Foundation, CF Community, CF News, Research, Therapies
March 20, 2019

SOURCE  Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)-Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points...